drugset / Trial / NCT04835584
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.
Timeline
- Start
- 2021-05-07
- Primary completion
- 2024-12-31
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Navtemadlin | Small molecule | — | Oral |
| Subject | Nilotinib | Small molecule | — | Oral |
| Subject | dasatinib anhydrous | Small molecule | — | Oral |